Table 3. Treatment modalities and outcomes in patients with pulmonary mucormycosis.
| Variables | Total (n=20) | No surgery (n=9) | Surgery (n=11) | P value |
|---|---|---|---|---|
| IV amphotericin B | 20 [100] | 9 [100] | 11 [100] | 1.0 |
| Amphotericin B deoxycholate | 6 (30.0) | 3 (33.3) | 3 (27.3) | |
| Amphotericin B, liposomal* | 14 (70.0) | 6 (66.7) | 8 (72.7) | |
| IV amphotericin B duration, days | 26.0 (15.0–41.0) | 15.0 (9.5–47.5) | 38.0 (23.5–41.0) | 0.119 |
| Symptom to treatment**, days | 14.0 (8.3–29.5) | 16.0 (11.0–27.0) | 10.0 (7.5–30.0) | 0.493 |
| Oral posaconazole | 5 (25.0) | 0 | 5 (45.5) | 0.069 |
| Oral posaconazole duration, days | 31.0 (17.5–77.5) | NA | 31.0 (17.5–77.5) | NA |
| Lung resection surgery | 11 (55.0) | 0 | 11 [100] | NA |
| Limited resection | 5 | 0 | 5 | |
| Lobectomy | 5 | 0 | 5 | |
| Pneumonectomy | 1 | 0 | 1 | |
| Treatment outcomes | ||||
| Survived | 10 (50.0) | 1 (11.1) | 9 (81.8) | 0.007 |
| Follow-up duration | 84.5 (12.8–534.8) | 12.0 (8.0–37.0) | 354.0 (108.0–1492.0) | 0.001 |
Values are number (%) or median (interquartile range). *, amphotericin B deoxycholate was used initially in five patients, followed by liposomal amphotericin B; **, median time between onset of first symptoms and initiation of intravenous amphotericin B. IV, intravenous; NA, not applicable.